Diligence memo · auto-generated · as of July 2, 2026
Tenax Therapeutics, Inc.
Tenax Therapeutics, Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Tenax Therapeutics, Inc. operates in Pharmaceuticals, based in CHAPEL HILL.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Tenax Therapeutics, Inc. has raised $138M in disclosed capital across 9 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $100M on 2024-08-08.
Most recent recorded round closed around 2024-08-08.
Valuation (modeled)modeled
Provath models Tenax Therapeutics, Inc. at approximately $841M (range $324M–$1.3B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.46× the median modeled value of Series C Pharmaceuticals companies in 2022–2024 (30 peers) — value vs value, same stage and era. Within the normal band (146% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 23 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 12.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 94% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: Vigil Neuroscience, Inc., Leap Therapeutics, Inc., Alimera Sciences Inc, VYNE Therapeutics Inc., Lusaris Therapeutics, Inc..
Peoplefiled
24 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.